Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma (vol 127, pg 2561, 2016)

被引：0
|
作者：
Baz, R. C.
Martin, T. G., III
Lin, H-Y
机构：
来源：
BLOOD | 2016年 / 128卷 / 03期
关键词：
D O I：
10.1182/blood-2016-06-721886
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：461 / 461
页数：1
相关论文
共 50 条
  • [1] Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma
    Baz, Rachid C.
    Martin, Thomas G., III
    Lin, Hui-Yi
    Zhao, Xiuhua
    Shain, Kenneth H.
    Cho, Hearn J.
    Wolf, Jeffrey L.
    Mahindra, Anuj
    Chari, Ajai
    Sullivan, Daniel M.
    Nardelli, Lisa A.
    Lau, Kenneth
    Alsina, Melissa
    Jagannath, Sundar
    BLOOD, 2016, 127 (21) : 2561 - 2568
  • [2] Pomalidomide, Cyclophosphamide, and Dexamethasone Is Superior to Pomalidomide and Dexamethasone in Relapsed and Refractory Myeloma: Results of a Multicenter Randomized Phase II Study
    Baz, Rachid
    Martin, Thomas G.
    Alsina, Melissa
    Shain, Kenneth H.
    Cho, Hearn J.
    Wolf, Jeffrey L.
    Mahindra, Anuj
    Chari, Ajai
    Sullivan, Daniel M.
    Nardelli, Lisa A.
    Lau, Kenneth
    Zhao, Xiuhua
    Lin, Hui-Yi
    Jagannath, Sundar
    BLOOD, 2014, 124 (21)
  • [3] A phase II study of pomalidomide, daily oral cyclophosphamide, and dexamethasone in relapsed/refractory multiple myeloma
    Van Oekelen, Oliver
    Parekh, Samir
    Cho, Hearn J.
    Vishnuvardhan, Nivetha
    Madduri, Deepu
    Richter, Joshua
    Ip, Chun
    Lau, Kenneth
    Florendo, Erika
    Mancia, Ines S.
    Thomas, Joanne
    Verina, Daniel
    Chan, Elaine
    Zarychta, Katarzyna
    La, Lisa
    Strumolo, Gina
    Melnekoff, David T.
    Leshchenko, Violetta V.
    Kim-Schulze, Seunghee
    Couto, Suzana
    Wang, Maria
    Pierceall, William E.
    Thakurta, Anjan
    Lagana, Alessandro
    Jagannath, Sundar
    Chari, Ajai
    LEUKEMIA & LYMPHOMA, 2020, 61 (09) : 2208 - 2215
  • [4] Phase 2 study of clarithromycin, pomalidomide, and dexamethasone in relapsed or refractory multiple myeloma
    Mark, Tomer M.
    Forsberg, Peter A.
    Rossi, Adriana C.
    Pearse, Roger N.
    Pekle, Karen A.
    Perry, Arthur
    Boyer, Angelique
    Tegnestam, Linda
    Jayabalan, David
    Coleman, Morton
    Niesvizky, Ruben
    BLOOD ADVANCES, 2019, 3 (04) : 603 - 611
  • [5] Randomized Phase 3 Study of Pomalidomide Cyclophosphamide Dexamethasone (PCD) Versus Pomalidomide Dexamethasone (PD) in Relapse or Refractory Myeloma: An Asian Myeloma Network (AMN) Study
    Song, Yang
    Kim, Jin Seok
    Chim, C. S.
    Lee, Je-Jung
    Yoon, Sung-Soo
    Ng, Soo Chin
    Gan, Gin Gin
    Handa, Hiroshi
    Jen, Wei-Ying
    Li, Xinhua
    Pokharkar, Yogesh Mahadev
    Durie, Brian G. M.
    Chng, Wee-Joo
    BLOOD, 2023, 142
  • [6] A randomized phase 2 study of pomalidomide/dexamethasone with or without elotuzumab in patients with relapsed/refractory multiple myeloma.
    San Miguel, Jesus
    Raab, Marc S.
    Goldschmidt, Hartmut
    Lonial, Sagar
    Richardson, Paul G.
    Shelat, Suresh
    Bleickardt, Eric W.
    Palumbo, Antonio
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [7] Pomalidomide, cyclophosphamide, and prednisone for relapsed/refractory multiple myeloma: a multicenter phase 1/2 open-label study
    Larocca, Alessandra
    Montefusco, Vittorio
    Bringhen, Sara
    Rossi, Davide
    Crippa, Claudia
    Mina, Roberto
    Galli, Monica
    Marcatti, Magda
    La Verde, Giacinto
    Giuliani, Nicola
    Magarotto, Valeria
    Guglielmelli, Tommasina
    Rota-Scalabrini, Delia
    Omede, Paola
    Santagostino, Alberto
    Baldi, Ileana
    Carella, Angelo Michele
    Boccadoro, Mario
    Corradini, Paolo
    Palumbo, Antonio
    BLOOD, 2013, 122 (16) : 2799 - 2806
  • [8] Carfilzomib, Pomalidomide and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma Patients: A Multicenter, Open Label Phase 1/2 Study
    Bringhen, Sara
    Oliva, Stefania
    Liberati, Anna Marina
    Belotti, Angelo
    Larocca, Alessandra
    Bonello, Francesca
    Gaidano, Gianluca
    Bertazzoni, Paola
    Esma, Fabrizio
    Stocchi, Raffaella
    Malfitano, Alessandra
    Ribolla, Rossella
    Di Sano, Chiara
    Aschero, Simona
    Patriarca, Francesca
    De Paoli, Lorenzo
    Cafro, Anna Maria
    Sonneveld, Pieter
    Palumbo, Antonio
    Boccadoro, Mario
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 (01): : E59 - E59
  • [9] Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study (vol 123, pg 1826, 2014)
    Richardson, P. G.
    Siegel, D. S.
    Vij, R.
    BLOOD, 2014, 123 (20) : 3208 - 3209
  • [10] A Phase II Study of Pomalidomide, Daily Low Dose Oral Cyclophosphamide, and Dexamethasone in Relapsed/Refractory Multiple Myeloma
    Chari, Ajai
    Cho, Hearn Jay
    Parekh, Samir
    Lau, Kenneth
    Morgan, Gillian
    Catamero, Donna
    Cortes, Melissa
    Curtis, Meredith
    Escalon, Juliet
    Florendo, Erika
    Verina, Daniel
    Stevens, Nadege
    Chan, Elaine
    Garcia, Katarzyna
    La, Lisa
    Shields, Marisa
    Strumolo, Gina
    Jagannath, Sundar
    BLOOD, 2016, 128 (22)
12345